New clinical data surrounding Retatrutide , specifically the high-dose formulation branded as ZPHC, indicate a impressive effect on body mass loss and associated chronic illnesses . Scientists believe that this dual acting , influencing both GLP-1 and GIP receptors , could provide a substantial